New Research Highlights Thymus's Unsung Role in Adult Health and Longevity

New research suggests that the health of the thymus, an organ traditionally believed to be largely inactive in adulthood, is associated with increased longevity, reduced risk of certain diseases, and improved responses to cancer immunotherapy. These groundbreaking findings challenge long-held beliefs about the thymus's role in adult immune function and overall well-being.

Two separate studies, published in Nature, utilized artificial intelligence to analyze routine computed tomography (CT) scans, indicating a more significant role for the thymus in adult immune function and overall health than previously understood.

The Thymus and Its Historical Understanding

The thymus is a small organ located in the chest that plays a critical role in the maturation and training of T cells, which are essential components of the immune system. Historically, it was widely believed that the thymus largely atrophied and became inactive after puberty, with its function diminishing significantly in adulthood.

The recent studies present findings that challenge this long-held view by examining thymic characteristics in thousands of adults.

Associations with Longevity and Disease Risk

One study, involving over 25,000 adults from a lung cancer screening trial and more than 2,500 participants from the Framingham Heart Study, assessed thymic health based on its size, shape, and composition as observed in CT scans.

Individuals with higher thymic health scores exhibited significantly improved health outcomes across several critical indicators.

Key findings from this research include:

Individuals with higher thymic health scores exhibited approximately a 50% lower risk of death from all causes.
They also showed a 63% lower risk of cardiovascular-related death.
A 36% lower risk of developing lung cancer was observed in this group.
These associations remained statistically significant even after adjusting for factors such as age and other health variables.

Researchers hypothesize that a decline in thymic health and T cell diversity may reduce the immune system's capacity to respond effectively to new threats. The study also noted that factors such as chronic inflammation, smoking, and high body weight were associated with poorer thymic health.

Impact on Cancer Immunotherapy Outcomes

A separate study focused on the link between thymic health and outcomes for cancer patients receiving Immune Checkpoint Inhibitors (ICIs). This analysis included a real-world cohort of 3,476 patients with various cancer types and an independent cohort of over 1,200 immunotherapy-treated patients.

Stronger thymic health was associated with improved outcomes across multiple cancer types, suggesting its critical role in the effectiveness of immunotherapy.

The findings indicated:

Stronger thymic health was associated with improved outcomes across multiple cancer types, including lung cancer, melanoma, breast cancer, and renal cancer.
Patients with higher thymic health showed a 37% lower risk of cancer progression and a 44% lower risk of death after receiving immunotherapy.
These associations persisted even after accounting for various patient, tumor, and treatment characteristics.

The observed poorer clinical outcomes in individuals with lower thymic health are attributed, in part, to a reduction in naive T cell output, supported by evidence of higher thymic activity readouts (sjTRECs) and increased T cell diversity in patients with high thymic health. This suggests that the state of an individual's adaptive immune system is a critical factor in their response to immunotherapy.

Potential as a Biomarker and Clinical Implications

The research suggests that thymic health, quantifiable through routine thoracic CT scans, could serve as a prognostic biomarker for immuno-oncology. This host-specific measure is independent of tumor characteristics, unlike many existing cancer biomarkers, and could potentially be used alone or in combination with other markers such as PD-L1 and TMB.

Potential clinical implications include:

Accelerating the adoption of immunotherapy in new indications.
Identifying patients at higher risk of poor outcomes, potentially preventing non-beneficial immunotherapy.
Improving patient quality of life by reducing unnecessary adverse events and potentially lowering healthcare costs.

The findings also raise the possibility that maintaining thymic health could influence long-term benefits from systemic cancer therapies and may have broader implications for personalized cancer treatment, including considerations for thymic preservation in cardiothoracic surgery and radiation oncology.

Study Strengths and Limitations

The studies investigated various cancer types across multiple independent cohorts, providing evidence for the associations observed. A strength noted is that thymic health is a host-specific measure, independent of the tumor.

However, the researchers caution that these findings require further confirmation in future studies. Limitations include that patients in some cohorts were predominantly white, necessitating testing in diverse ethnic populations. Generalizability across different scanners, institutions, and countries must also be proven, and universal clinical cut-offs for thymic health have not yet been established. The studies did not directly assess whether modifying lifestyle factors improves thymic function, nor did they include a matched non-immunotherapy comparator to directly evaluate predictive implications. The imaging method is not yet ready for routine clinical use.

Funding for this research was provided by organizations including the National Institutes of Health, European Research Council, Deutsche Forschungsgemeinschaft (DFG), Lundbeck Foundation, Novo Nordisk Foundation, and the Savvaerksejer Jeppe Juhl og Hustru Ovita Juhl Research Stipend.